Virtual Library

WS08.05 - Minimal Residual Disease (MRD) Negative: Potential for Cure in Resected Oncogene Driven NSCLC? Chinese Perspective

21:10 - 21:30  |  Author(s): Jia-Tao Zhang

WS08.06 - Could MRD Change Our Clinical Practice? North American Perspective

21:30 - 21:50  |  Author(s): Aadel Chaudhuri

WS08.07 - How to Use Liquid Biopsy to Monitor Treatment Efficacy for Advanced Driven NSCLC

21:50 - 22:10  |  Author(s): Jie Hu

WS08.09 - Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer

22:30 - 22:40  |  Author(s): Si-Yang Maggie Liu

WS08.10 - Toripalimab in Combination with CIK Cells in Patients with Advanced NSCLC: An Exploratory Study

22:40 - 22:50  |  Author(s): Baohui Han

WS08.13 - Activity of aPD1-MSLN-CART Cells Against Metastatic Lung Cancer in a Phase 1 Trial

23:20 - 23:21  |  Author(s): Lingjuan Chen

WS08.14 - Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-Negative NSCLC

23:21 - 23:22  |  Author(s): Lin Wu

WS08.15 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC

23:22 - 23:23  |  Author(s): Jun Zhao

WS08.16 - The Increase of Blood Intratumor Heterogeneity is Associated with Unfavorable Outcomes of ICIs Plus Chemotherapy in NSCLC

23:23 - 23:24  |  Author(s): Juan Zhou

WS08.17 - Utilization of Tumor Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer

23:24 - 23:25  |  Author(s): Peng Song

WS08.18 - Discussant for Poster 1 - 5

23:25 - 23:40  |  Author(s): Xiaorong Dong

WS08.24 - Discussant for Poster 6 - 10

23:35 - 23:50  |  Author(s): Ming Fang Zhao

WS08.19 - Phase Il Trial of Neoadjuvant Tislelizumab with Chemotherapy for Resectable Stage IIB-III Non-small Cell Lung Cancer

23:40 - 23:41  |  Author(s): Yao-Bin Lin

WS08.20 - Comprehensive Analysis of a Dendritic Cell Marker Genes Signature to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma

23:41 - 23:42  |  Author(s): Yuan Li

WS08.21 - Immune Evolution of Metastases & Underlying Molecular Mechanisms in Non-small Cell Lung Cancer

23:42 - 23:43  |  Author(s): Wen-Fang Tang

WS08.22 - Neoadjuvant Toripalimab Combination in Patients with Stage IIB-IIIB NSCLC: A Single-arm, Phase 2 Trial (Renaissance Study)

23:43 - 23:44  |  Author(s): Shi Yan

WS08.23 - Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer with Four Structure-Based EGFR-Mutation Subgroups

23:44 - 23:45  |  Author(s): LinPing Gu

EP08.01-070 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC

EP08.01-071 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC

EP08.01-085 - Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer

EP08.02-064 - ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)

EP08.02-049 - A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, In Patients With Advanced Solid Tumors With HER2 Aberrations

EP08.02-063 - SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC

EP08.02-108 - Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA Study

EP10.01-010 - Real-world Study of the Incidence and Risk Factors of Venous Thromboembolism in Chinese Lung Cancer (RIVAL)

EP16.01-025 - Immune Evolution of Metastases & Underlying Molecular Mechanisms in Non-small Cell Lung Cancer

EP16.02-024 - Plasma ctDNA Organ-Specific Genomic Patterns and Origination Analysis in Advanced Non-Small Cell Lung Cancer

MA02.05 - Dynamic Mutation Profiles of SCLC Transformation in NSCLC Patients Harboring Concurrent EGFR/TP53/RB1 Mutations

10:57 - 11:02  |  Author(s): Jie Huang

OA02.05 - Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study

12:22 - 12:32  |  Author(s): Yi-Long Wu

OA03.05 - Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C

14:52 - 15:02  |  Author(s): Michael Thomas

OA15.06 - Pooled Analysis of Outcomes With Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer

15:02 - 15:12  |  Author(s): Delvys Rodriguez-Abreu